Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.55 |
| ▸ | ERN1 | O75460 | 11/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KLF10 | Q13118 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 1/20 | 0.44 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.43 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15746144 | 0.93 | ESR1 (0.69) | ESR1ERN1MAPTSMN1; SMN2KLF10 | |
| SCHEMBL10331735 | 0.93 | ESR1 (0.55) | ESR1ERN1MAPTSMN1; SMN2KLF10 | |
| SCHEMBL3450817 | 0.91 | ESR1 (0.47) | ESR1ERN1MAPTSMN1; SMN2KLF10 | |
| SCHEMBL9291079 | 0.91 | ESR1 (0.52) | ESR1ERN1MAPTSMN1; SMN2KLF10 | |
| SCHEMBL15746146 | 0.91 | ESR1 (0.56) | ESR1ERN1MAPTSMN1; SMN2KLF10 | |
| SCHEMBL3451314 | 0.88 | ESR1 (0.50) | ESR1ERN1MAPTSMN1; SMN2KLF10 | |
| SCHEMBL332380 | 0.88 | MAPT (0.62) | ERN1MAPTSMN1; SMN2ALOX15CDK1 | |
| SCHEMBL11417093 | 0.86 | MAPT (0.61) | ERN1MAPTSMN1; SMN2ALOX15CDK1 | |
| SCHEMBL16130218 | 0.86 | ERN1 (0.50) | ERN1MAPTSMN1; SMN2CDK1TRIM24 | |
| SCHEMBL14849044 | 0.85 | ERN1 (0.49) | ERN1MAPTSMN1; SMN2CDK1TRIM24 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110204485-B | Synthesis method and application of bis-salicylaldehyde-condensed 2-pyridine formhydrazide Schiff base | 哈尔滨理工大学 | 2022-08-09 | — | — | CN | claimed |
| US-RE43067-E1 | Method for producing new polynuclear poly(formylphenol) | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-7875743-B2 | such as bis(3-formyl-4-(4-methoxycarbonylphenyl)methoxyphenyl)methane, by reacting bis(hydroxymethyl-hydroxyphenyl)alkane with hexamethylene tetramine in presence of acid and hydrolyzing, then reacting with halogenated alkoxycarbonyl hydrocarbon in presence of base | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2011-01-25 | — | — | US | disclosed |
| US-7750190-B2 | reacting hexamethylene tetramine in presence of acid; industrial scale; photoresists | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2010-07-06 | — | — | US | disclosed |
| US-20100016633-A1 | such as bis(3-formyl-4-(4-methoxycarbonylphenyl)methoxyphenyl)methane, by reacting bis(hydroxymethyl-hydroxyphenyl)alkane with hexamethylene tetramine in presence of acid and hydrolyzing, then reacting with halogenated alkoxycarbonyl hydrocarbon in presence of base | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| WO-2009116665-A1 | PROCESS FOR PRODUCTION OF 2-HYDROXYARYL ALDEHYDE COMPOUND | 日産化学工業株式会社 (JP) | 2009-09-24 | — | — | WO | disclosed |
| US-20090182175-A1 | METHOD FOR PRODUCING NEW POLYNUCLEAR POLY(FORMYLPHENOL) | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
| WO-2008142316-A1 | CYCLODEXTRINE OLIGOMERS AS VECTORS OF ACTIVATED MOLECULES | BIOCYDEX (FR) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182175-A1 | METHOD FOR PRODUCING NEW POLYNUCLEAR POLY(FORMYLPHENOL) | PCBP1, FPR2, PNKP | ESR1 4141/4885ERN1 2895/4885MAPT 3943/4885 |
| US-20100016633-A1 | such as bis(3-formyl-4-(4-methoxycarbonylphenyl)methoxyphenyl)methane, by reacting bis(hydroxymethyl-hydroxyphenyl)alkane with hexamethylene tetramine in presence of acid and hydrolyzing, then reacting with halogenated alkoxycarbonyl hydrocarbon in presence of base | PAH, PGM2, HNMT | ESR1 2989/4885ERN1 3647/4885MAPT 3944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.